Huonslab eyes speedy anticancer drug delivery with new patent

South Korean biotech Huons Global Co. said on Tuesday that its research and development unit Huonslab has issued a domestic patent claiming a techno...

SK Biopharm mulls acquiring firms, drug sales rights in US

SAN DIEGO, California -- South Korea’s SK Biopharmaceuticals Co. is considering acquiring firms in the US, or the sales rights to some of thei...

Handok gets Biocon's obesity drug exclusive distribution in S.Korea

South Korean pharmaceutical company Handok Inc. announced on Friday that it signed an exclusive domestic sales and distribution agreement with India...

Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

KT, Nokia to collaborate on global 6G research

South Korea's KT Corp. announced on Wednesday that it signed a business agreement with global mobile communications equipment manufacturer Nokia Cor...

S.Korean anti-obesity drugmakers eye niche demand

The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...

MBK, Air Premia team up for Asiana’s cargo unit; Jeju Air exits

South Korea's low-cost carrier Air Premia Inc. has teamed up with North Asia-focused private equity firm MBK Partners to win Asiana Airlines Inc.'s ...

HK inno.N to release K-CAB in MENA market

South Korean bio-health company HK inno.N announced on Tuesday that it signed a contract with Saudi Arabian local pharmaceutical company Tabuk Pharm...

Blackstone signs over $1 bn deal with MBK for 1st exit in Korea

Private equity giant Blackstone Inc. is set to mark its first exit from South Korea by selling a 71.25% stake in the holding firm of Geo-Young Corp....

Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

NPS to vote in favor of KT&G CEO candidate Bang

South Korea’s National Pension Service (NPS), the world’s third-largest pension fund, is slated to vote in favor of the KT&G Corp. b...

Drug maker Boryung targets its highest-ever sales in 2024

Boryung Corp., formerly Boryung Pharmaceutical Co., aims to join the 1 trillion won ($748 million) sales club this year, driven by new chronic disea...

Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

ISS urges KT&G shareholders to vote against CEO candidate Bang

Global leading proxy advisor Institutional Shareholder Services Inc. (ISS) has recommended that stakeholders of South Korean tobacco maker KT&G ...

Vivid Health gets seed round from Kakao Ventures

Vivid Health, a South Korean startup that operates an obesity treatment management platform announced on Wednesday that it got a seed round investme...

Korea's NH Investment shortlists 3 CEO candidates

South Korean brokerage house NH Investment & Securities Co. has shortlisted three candidates for its next chief executive as the current CEO Jeo...

Tobacco maker KT&G names its COO as final CEO candidate

South Korea’s KT&G Corp., the world’s leading tobacco maker, appointed its Chief Operating Officer Bang Kyung-man as the final candi...

Daewoong Pharmaceutical digitizes DB of 800 mn chemical compounds

South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combine...

SK Biopharm targets $311 mn for Cenobamate US sales

South Korea's SK Biopharmaceuticals targeted 416 billion won ($311 million) for its epilepsy treatment Cenobamate in the US market this year. SK Bi...

Samsung Asset to launch S.Korea's first obesity treatment ETF

Korea Exchange announced on Thursday that it will list Samsung Asset Management's "KODEX Global Obesity Treatment Top 2 Plus exchange-traded fund (E...

Samsung Biologics signs ADC CDO deal with LegoChem Bio

Samsung Biologics Co. has agreed with South Korean biotech company LegoChem Biosciences Inc. to provide contract development organization (CDO) serv...

Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries...

Kobiolabs gets Chinese patent for obesity treatment strain

South Korean microbiome-based new drug development company Kobiolabs Co. announced on Wednesday that it has a patent for its obesity treatment strai...

LG Chem to start phase 3 for head, neck cancer drug in US

South Korea’s LG Chem Ltd. announced on Wednesday that its US-based subsidiary Aveo Pharmaceuticals will start Phase 3 clinical trials for its...

Orion to buy control of biotech startup LegoChem for $415 mn

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

OCI-Hanmi merger to create Korea’s Bayer: OCI Chairman

Merging into one team, OCI Group and Hanmi Pharmaceutical Group will leap forward to be a global novel drug manufacturing and biotechnology innova...

JW Pharma takes gout drug Epaminurad to Malaysia for phase 3

South Korea's JW Pharmaceutical Corp., announced on Monday that it has received approval from the Malaysian National Pharmaceutical Regulatory Age...

Celltrion to expand Yuflyma supply network in Europe

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment ...

Celltrion applies for interchangeability of Yuflyma in US

South Korea's Celltrion Inc. announced on Wednesday that it has applied to the US Food and Drug Administration (FDA) for a modified approval to repl...